What is Rocklatan?
Rocklatan is a medication prescribed to reduce elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension [1]. Its active ingredient is netarsudil, which is administered as eye drops [2].
How does Rocklatan work to lower eye pressure?
Rocklatan works by inhibiting the Rho-kinase (ROCK) pathway [2]. This inhibition increases the outflow of aqueous humor through the trabecular meshwork, which is the eye's primary drainage system. By facilitating this drainage, Rocklatan helps to lower intraocular pressure [2][3].
When did Rocklatan become available?
Rocklatan was approved by the U.S. Food and Drug Administration (FDA) in March 2019 [1].
What are the potential side effects of Rocklatan?
The most common side effect reported with Rocklatan is conjunctival hyperemia, which is redness of the eye [1]. Other reported side effects include eye pain, corneal verticillata (a condition where drug deposits form in the cornea), and instillation site pain [1][4].
How does Rocklatan compare to other glaucoma treatments?
Rocklatan is a once-daily topical medication. Unlike some other glaucoma treatments that primarily target aqueous humor production, Rocklatan's mechanism of action focuses on increasing aqueous humor outflow [2][3]. This dual mechanism offers an alternative approach for managing IOP [2]. For example, prostaglandin analogs are a common class of glaucoma medications that primarily work by increasing uveoscleral outflow [3].
When does the patent for Rocklatan expire?
Information regarding the specific patent expiry dates for Rocklatan is available through patent tracking resources like DrugPatentWatch.com [5].
Who manufactures Rocklatan?
Rocklatan is manufactured by Nicox Ophthalmics, Inc. [1].